Navigation Links
BioCryst Provides Update Regarding Peramivir for Influenza
Date:9/30/2009

am P. Sheridan, Chief Medical Officer at BioCryst. "The need for such studies is clear; there are currently no anti-viral agents approved for this seriously ill patient population, and no intravenous or injectable forms of any anti-viral agent are approved for any influenza indication."

One Phase 3 study is a multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of i.v. peramivir administered once-daily for five days in addition to standard of care (SOC), compared to standard of care alone, in adults and adolescents who are hospitalized due to serious influenza. The other Phase 3 study is an open-label, randomized study of the anti-viral activity, safety and tolerability of i.v. peramivir 600 mg administered once-daily compared with split doses twice-daily for five days in adult and adolescent hospitalized subjects with confirmed or suspected influenza infection. The combined enrollment target for these studies is approximately 700 patients. Further details regarding these Phase 3 study designs are available at clinicaltrials.gov at this link:

http://www.clinicaltrials.gov/ct2/results?term=Peramivir+HHS+Phase+3&recr=Open

About peramivir

Peramivir is an anti-viral agent that was discovered by BioCryst which inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in patients with complicated and uncomplicated influenza. BioCryst's partner, Shionogi & Co., Ltd. is currently preparing to file for regulatory approval in Japan this year.

About Influenza

Influenza (the flu) is a contagious respiratory illness caused by

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
2. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
3. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
4. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
5. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
6. BioCryst Updates Peramivir Clinical Development Plan
7. BioCryst Provides Forodesine HCl Update
8. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
9. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
10. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
11. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 Silver Creek Pharmaceuticals, Inc. ... Research (SBIR) grant from the National Institute of Health ... San Francisco based biotechnology company that ... tissues damaged by disease. This award will be used ... heart tissue following a heart attack. Silver ...
(Date:5/5/2015)... May 5, 2015 GW Pharmaceuticals plc ... a biopharmaceutical company focused on discovering, developing and ... platform, announced today the closing of the previously ... GW of 1,600,000 American Depositary Shares (ADSs) at ... proceeds of approximately $179.2 million (before deducting underwriting ...
(Date:5/5/2015)...  IBM Watson Health (NYSE: IBM ) today announced ... Mayo Clinic to advance patient health by applying the ... As Watson,s capabilities are applied to EHRs, ... of the medical factors that could impact an individual,s health ... customers – some of the largest and most-recognized healthcare ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 4IBM Watson Health, Epic and Mayo Clinic to Unlock New Insights from Electronic Health Records 2IBM Watson Health, Epic and Mayo Clinic to Unlock New Insights from Electronic Health Records 3IBM Watson Health, Epic and Mayo Clinic to Unlock New Insights from Electronic Health Records 4
... 5, 2011 Jennerex, Inc., a private clinical-stage ... of first-in-class targeted oncolytic products for cancer, and ... specialized in the development of immunotherapeutic products, today ... 2 clinical studies of JX-594 were presented in ...
... Pharmaceuticals, Inc. (NASDAQ: QCOR ) today announced preliminary ... The Company announced the preliminary metrics in advance of the ... Executive Officer of Questcor, will present on Tuesday, April 5, ... web cast of the presentation during or after the event, ...
Cached Medicine Technology:Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 2Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 3Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 4Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 5Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 2Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 3Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 4Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 5Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 6Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 7Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 8
(Date:5/6/2015)... NC (PRWEB) May 06, 2015 LINET ... Award of Charlotte in the small business category. The ... The Mayor’s International Community Award is given on an ... area that exhibit outstanding contributions to philanthropy. Since ... the Mayor have hosted the Mayor’s International Community Awards. ...
(Date:5/6/2015)... Lewisville, TX (PRWEB) May 06, 2015 ... (NYSE:ADPT) opened its first freestanding emergency room in Chandler ... Dignity Health Arizona General Hospital, which is also part ... To celebrate the grand opening, Dignity Health Arizona General ... the Chandler Chamber of Commerce and donated $5,000 to ...
(Date:5/5/2015)... It’s not your usual Veterans Affairs outreach ... cars and motorcycles to the 3rd Annual “Crusin Lincoln” Show ... at the Lincoln VA Clinic, 600 S. 70th St. , ... out each other’s rides, but also to talk to employees ... , Staff from the VA Nebraska-Western Iowa Health Care ...
(Date:5/5/2015)... 05, 2015 With the FCPX LUT: Monochromatic ... and easily add washed color grades to footage. A LUT ... modifying an image. The LUT changes every pixel's color to ... with 90 washed CUBE LUT files. , This plugin was ... give any footage a washed look. , CUBE LUT ...
(Date:5/5/2015)... The Journal of Pain Research has ... improve the management of chronic non-cancer pain in ... program ” , As corresponding author Professor Lyne ... and family members, managers, and researcher, identified challenges ... “work in silos”, lack of awareness regarding chronic ...
Breaking Medicine News(10 mins):Health News:LINET Americas Wins The Mayor's International Community Award in Charlotte 2Health News:Dignity Health and Adeptus Health Opened First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health Opened First Freestanding Emergency Room in Chandler, Arizona 3Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2
... Americans will be diagnosed at some point in their lives ... One of the most common types, especially among women, is ... will be diagnosed with breast cancer in 2009, and more ... alone. One of the professions at the frontlines in ...
... , Teva Pharmaceuticals Hosting Local Roundtable as ... , PHILADELPHIA, JULY 24 According ... between 2000 and 2007. In an effort to bring awareness ... leading generic pharmaceutical company, is hosting a roundtable forum on July ...
... drop in estrogen, experts say , FRIDAY, July 24 ... involves removal of both ovaries, nearly doubles a younger ... study has found. , "It,s possible that vulnerability to ... in estrogen levels or potentially long-term use of hormone ...
... , PITTSBURGH, July 24 ... organizations in Pennsylvania to assist programs that are supported by ... Grant Program, which reinforces the company,s appreciation for those employees ... , Highmark recognizes that its ...
... PITTSBURGH, July 24 Cardiorobotics, Inc., a medical device company ... of surgical and interventional applications has closed on an $11.6 ... was led by Eagle Ventures and its co-investors, the Pittsburgh ... investors. , , Funds raised ...
... COLUMBIA, S.C., July 24 UCI Medical Affiliates, ... the former Executive Vice-President of Finance, Chief Financial Officer, and ... on July 23, 2009 in federal court to criminal charges ... the Securities and Exchange Commission. On the eight reports ...
Cached Medicine News:Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 2Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 3Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 4Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 5Health News:Government Officials, Community Leaders Invited to Come Together to Examine the Rising Cost of Healthcare 2Health News:Ovary Removal May Play a Role in Lung Cancer 2Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 2Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 3Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 4Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 5Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 6Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 7Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 8Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 9Health News:Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery 2Health News:Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery 3Health News:Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery 4Health News:UCI Medical Affiliates, Inc.'s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges 2
...
Designed to minimize emblolic debris in SVGs and carotids...
... EECP therapy extends the ability ... to treat coronary artery disease, and ... of participating in the treatment of ... drugs. Vasomedical's EECP therapy provides a ...
... The dual lumen petite ... 1.0 mm catheter (each lumen) ... Dual oval lumen catheters offer ... maximum catheter strength. Dual lumen ...
Medicine Products: